Studies have shown that different percentages of body fat can alter the way drugs are distributed in the body. This study will use blood samples taken at different time points for patients taking acyclovir to determine if higher body weights affect drug exposure. The information gathered from this study will help understand if patients with higher body weights need a different dosing plan. Patients receiving acyclovir as standard of care will be enrolled into this study. They will have blood draws once before they take acyclovir and 10 times after they take the acyclovir (over a total of 12 hours). These patients will be in the hospital already and will not need to make additional trips back to have blood drawn. A total of about 4-5 tablespoons of blood will be drawn for this study. 7 obese patients and 7 matched, non-obese patients will be enrolled into this study.
Study Type
OBSERVATIONAL
Enrollment
14
West Virginia University Hospitals Mary Babb Randolph Cancer Center
Morgantown, West Virginia, United States
Systemic clearance of acyclovir in obese and non-obese patients
Time frame: 12 hours after acyclovir dose
Alpha and beta half-life of acyclovir in obese and non-obese patients
Time frame: 12 hours after acyclovir dose
Maximum concentration (Cmax) of acyclovir in obese and non-obese patients
Time frame: 12 hours after acyclovir dose
Time to maximum concentration (Tmax) of acyclovir in obese and non-obese patients
Time frame: 12 hours after acyclovir dose
Volume of distribution (Vd and Vdss) of acyclovir in obese and non-obese patients
Time frame: 12 hours after acyclovir dose
Time that concentration is above IC50 for varicella and herpes viruses 4,5,6,7 for acyclovir in obese and non-obese patients
Time frame: 12 hours after acyclovir dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.